Plaque Psoriasis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie

The Key Plaque Psoriasis Therapies in the market include - AX-158, tapinarof cream, 1%, TAK-279, TQH3906 capsules, Apremilast, Cetaphil, LY3972406, GNR-068, D-2570, ZL-1102, ESK-001, Deucravacitinib, JNJ-77242113, and others.

DelveInsight's "Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Plaque Psoriasis, historical and forecasted epidemiology as well as the Plaque Psoriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Plaque Psoriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Plaque Psoriasis Market Forecast [https://www.delveinsight.com/sample-request/plaque-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Plaque Psoriasis Market Report:

*
The Plaque Psoriasis market size is estimated to grow with a significant CAGR during the study period (2019-2032)

*
In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis. The LTE trial included the 52-week POETYK PSO-1 and POETYK PSO-2 studies, involving 1,221 participants who received a 6mg daily dose of open-label Sotyktu.

*
In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled study includes three dosing groups to evaluate the treatment's safety, pharmacokinetics, and tolerability. Participants will receive either 0.25mg, 0.5mg, or 1mg doses of VYN202, or a placebo, administered once daily over a 12-week period.

*
In December 2024, Bristol Myers Squibb (NYSE: BMY) announced findings from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials assessing the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary endpoint, demonstrating a significantly higher percentage of Sotyktu-treated patients attaining an ACR20 response-indicating at least a 20% improvement in disease signs and symptoms-after 16 weeks of treatment compared to placebo.

*
In October 2024, InnoCare Pharma has reported that its Phase II clinical trial of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for psoriasis treatment achieved the primary endpoint. The multicenter, randomized, double-blind, placebo-controlled study aimed to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients with moderate-to-severe plaque psoriasis.

*
In August 2024, Amgen (NASDAQ:AMGN) announced that Otezla Registered (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are suitable candidates for phototherapy or systemic therapy. Currently, there are no other FDA-approved oral treatments for moderate to severe plaque psoriasis in this age group.

*
Plaque Psoriasis affected women more than it did men, according to DelveInsight's data. For example, in Japan in 2021, there were about 34,000 cases of Plaque Psoriasis in males and about 39,000 in females.

*
Key Plaque Psoriasis Companies: Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others

*
Key Plaque Psoriasis Therapies: AX-158, tapinarof cream, 1%, TAK-279, TQH3906 capsules, Apremilast, Cetaphil, LY3972406, GNR-068, D-2570, ZL-1102, ESK-001, Deucravacitinib, JNJ-77242113, and others

*
The Plaque Psoriasis epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases

*
The Plaque Psoriasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Plaque Psoriasis pipeline products will significantly revolutionize the Plaque Psoriasis market dynamics.

Plaque Psoriasis Overview

Plaque psoriasis is a chronic autoimmune skin condition characterized by the rapid buildup of skin cells, leading to the formation of thick, red, scaly patches, or plaques. These plaques often appear on the scalp, elbows, knees, and lower back, and may cause itching, discomfort, and inflammation. The condition is caused by an overactive immune system, which accelerates skin cell production. While the exact cause is unclear, genetics and environmental factors play a role. Plaque psoriasis is a lifelong condition, but its symptoms can be managed with treatments like topical therapies, phototherapy, and systemic medications.

Get a Free sample for the Plaque Psoriasis Market Report:

https://www.delveinsight.com/report-store/plaque-psoriasis-market [https://www.delveinsight.com/report-store/plaque-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Plaque Psoriasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Plaque Psoriasis Epidemiology Segmentation:

The Plaque Psoriasis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Plaque Psoriasis

*
Prevalent Cases of Plaque Psoriasis by severity

*
Gender-specific Prevalence of Plaque Psoriasis

*
Diagnosed Cases of Episodic and Chronic Plaque Psoriasis

Download the report to understand which factors are driving Plaque Psoriasis epidemiology trends @ Plaque Psoriasis Epidemiology Forecast [https://www.delveinsight.com/sample-request/plaque-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Plaque Psoriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Plaque Psoriasis market or expected to get launched during the study period. The analysis covers Plaque Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Plaque Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Plaque Psoriasis Therapies and Key Companies

*
AX-158: Artax Biopharma Inc

*
tapinarof cream, 1%: Dermavant Sciences, Inc.

*
TAK-279: Takeda

*
TQH3906 capsules: Chia Tai Tianqing Pharmaceutical

*
Apremilast: Amgen

*
Cetaphil: Galderma R&D

*
LY3972406: Eli Lilly and Company

*
GNR-068: AO GENERIUM

*
D-2570: InventisBio Co., Ltd

*
ZL-1102: Zai Lab

*
ESK-001: Alumis Inc

*
Deucravacitinib: Bristol-Myers Squibb

*
JNJ-77242113: Janssen Research & Development

Discover more about therapies set to grab major Plaque Psoriasis market share @ Plaque Psoriasis Treatment Market [https://www.delveinsight.com/sample-request/plaque-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Plaque Psoriasis Market Strengths

*
Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of PsA in the recent decade

*
Various screening tools, including self-administered questionnaires, have been developed to help dermatologists, rheumatologist, and general physicians to identify patients who might suffer from PsA

Plaque Psoriasis Market Unmet Needs

*
Lack of biomarkers

*
Challenges in current treatment options

*
Challenges in current guidelines

*
Poor disease understanding

*
Challenges in managing comorbidities

Scope of the Plaque Psoriasis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Plaque Psoriasis Companies: Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others

*
Key Plaque Psoriasis Therapies: AX-158, tapinarof cream, 1%, TAK-279, TQH3906 capsules, Apremilast, Cetaphil, LY3972406, GNR-068, D-2570, ZL-1102, ESK-001, Deucravacitinib, JNJ-77242113, and others

*
Plaque Psoriasis Therapeutic Assessment: Plaque Psoriasis current marketed and Plaque Psoriasis emerging therapies

*
Plaque Psoriasis Market Dynamics: Plaque Psoriasis market drivers and Plaque Psoriasis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Plaque Psoriasis Unmet Needs, KOL's views, Analyst's views, Plaque Psoriasis Market Access and Reimbursement

To know more about Plaque Psoriasis companies working in the treatment market, visit @ Plaque Psoriasis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/plaque-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Plaque Psoriasis Market Report Introduction

2. Executive Summary for Plaque Psoriasis

3. SWOT analysis of Plaque Psoriasis

4. Plaque Psoriasis Patient Share (%) Overview at a Glance

5. Plaque Psoriasis Market Overview at a Glance

6. Plaque Psoriasis Disease Background and Overview

7. Plaque Psoriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Plaque Psoriasis

9. Plaque Psoriasis Current Treatment and Medical Practices

10. Plaque Psoriasis Unmet Needs

11. Plaque Psoriasis Emerging Therapies

12. Plaque Psoriasis Market Outlook

13. Country-Wise Plaque Psoriasis Market Analysis (2019-2032)

14. Plaque Psoriasis Market Access and Reimbursement of Therapies

15. Plaque Psoriasis Market Drivers

16. Plaque Psoriasis Market Barriers

17. Plaque Psoriasis Appendix

18. Plaque Psoriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=plaque-psoriasis-market-predicted-to-see-upsurge-through-2032-highlights-delveinsight-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-biosciences-aclaris-therapeutics-abbvie]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.